Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021

Published:2022-03-15 Issue:3 Volume:5 Page:e222265
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Benjamin David J.¹,Xu Alexander²,Lythgoe Mark P.³,Prasad Vinay⁴

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Orange

2. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

3. Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, England

4. Department of Epidemiology and Biostatistics, University of California, San Francisco

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2790102/benjamin_2022_oi_220100_1646767780.6313.pdf

Reference24 articles.

1. Why advances in immunotherapy mean the golden age of oncology.;Landau;Oncol Times,2019

2. Assessment of new molecular entities approved for cancer treatment in 2020.;Smith;JAMA Netw Open,2021

3. New and emerging therapies for acute myeloid leukaemia.;Davis;J Investig Med,2018

4. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy.;Suzman;Oncologist,2019

5. Osimertinib: first global approval.;Greig;Drugs,2016

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey;JCO Oncology Practice;2024-07-15

2. Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies;Journal of Clinical Medicine;2024-06-05

3. Improved Dermatologist, Patient, and Oncologist Collaboration Needed During Cancer Drug Development;JAMA Dermatology;2024-06-01

4. Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi Arabia;F1000Research;2024-05-31

5. Cost effectiveness of immunotherapy combination therapies for endometrial cancer;Gynecologic Oncology Reports;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3